This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

Key Inclusion Criteria: * Male or female aged 18 to 65 years and in good general health * Moderate to severe AD for at least 6 months prior to Randomization * History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable * EASI score ≥ 16 at Screening and at Randomization * vIGA AD score ≥ 3 at Screening and at Randomization * AD involved BSA ≥ 10% at Screening and at Randomization Key Exclusion Criteria: * Any factors that in the Investigator's opinion would predispose the subject to develop an infection * Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status * Not able to tolerate SC drug administration * Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization